GSK: positive data for Covid-19 Beta vaccine
(CercleFinance.com) - Sanofi and GSK announce positive trial data for their bivalent D614 and Beta vaccine (B.
1.351), which they say is the first candidate to demonstrate efficacy, in a placebo-controlled trial and in the context of high circulation of the Omicron variant.
A primary vaccination with the beta antigen-containing vaccine candidate showed 64.7% efficacy against symptomatic infections in adults and 75.1% efficacy in participants previously infected with Covid-19.
For Omicron, sequencing analysis to date shows 72% efficacy in all adults and 93.2% efficacy in those previously infected with SARS-CoV-2.
This very first efficacy data, in an epidemic context dominated by the Omicron variant, therefore support the relevance of a vaccine containing the Beta antigen. The vaccine also showed a favourable safety and tolerance profile.
Copyright (c) 2022 CercleFinance.com. All rights reserved.